[GOVERNMENT POLICY]
US tariff / FDA action on Indian pharma
Sun Pharma, Dr Reddy's, Cipla — Indian generics under US tariff / FDA action risk
▼ Stocks under pressure8 cos
TORRENTPHARMPharma
Torrent Pharma
US generic exposure ~30-50% of revenue at risk
ZYDUSLIFEPharma
Zydus Lifesciences
US generic exposure ~30-50% of revenue at risk
BIOCONPharma
Biocon
US generic exposure ~30-50% of revenue at risk
SUNPHARMAPharma
Sun Pharma
US generic exposure ~30-50% of revenue at risk
DRREDDYPharma
Dr Reddy's Labs
US generic exposure ~30-50% of revenue at risk
DIVISLABPharma
Divi's Laboratories
US generic exposure ~30-50% of revenue at risk
CIPLAPharma
Cipla
US generic exposure ~30-50% of revenue at risk
AUROPHARMAPharma
Aurobindo Pharma
US generic exposure ~30-50% of revenue at risk
Historical examples
2025-04-08 — Trump tariff threat on pharma imports
See this signal live
Downstox PRISM monitors 54+ event patterns like this one in real time across the live news feed. When this signal fires, you'll see it on the geo-impact engine panel.
Open live PRISM dashboard →